Real-world Study of SPRINT 60-day Peripheral Nerve Stimulation (PNS) Corroborates Published Clinical Study Results
May 06, 2022 09:24 ET
|
SPR Therapeutics, Inc.
CLEVELAND, May 06, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced the publication of a study that evaluated the real-world impact of 60-day peripheral nerve stimulation (PNS) in the management...
Prolonged Temporary Neurostimulation Treatment Period Offered by the SPRINT® PNS System May Optimize Pain Management Care Pathway While Reducing Healthcare Costs
March 15, 2022 10:31 ET
|
SPR Therapeutics, Inc.
CLEVELAND, March 15, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced publication of a study in the Journal of Pain Research demonstrating how a longer initial treatment period may better...
The PNS Trifecta: All Three SPRINT® PNS System Abstracts Submitted to ASRA 2021 Pain Medicine Meeting Receive President’s Choice Award
November 18, 2021 12:32 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics has been honored with three President’s Choice Abstract Awards at the 20th Annual ASRA Pain Medicine Meeting taking place November 18-20...
FDA Clearance of an Expanded Indication for the SPRINT® PNS System Now Enables Treatment in Areas of the Head, Neck, and Torso
October 19, 2021 12:22 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Ohio, Oct. 19, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics® has obtained clearance from the U.S. Food and Drug Administration (FDA) of a broader indication for use for its SPRINT Peripheral...
SPR Therapeutics Closes $37 Million Growth Equity Financing for Commercial Expansion of its SPRINT® PNS System
October 18, 2021 09:17 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Oct. 18, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on providing patients with pain relief without opioids or surgery, announced today it has...
SPR Therapeutics CEO Maria Bennett Selected as Winner of EY Entrepreneur of the Year in East Central Region
August 06, 2021 10:00 ET
|
SPR Therapeutics, Inc.
CLEVELAND, Aug. 06, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics is proud to announce that President, Founder and CEO Maria Bennett has been selected as an Ernst & Young (EY) Entrepreneur Of The...
Multi-Center Study of SPRINT® PNS System for Chronic Low Back Pain Demonstrates Clinically Significant Improvements in Pain and Quality of Life
July 12, 2021 08:00 ET
|
SPR Therapeutics, Inc.
CLEVELAND, July 12, 2021 (GLOBE NEWSWIRE) -- In the largest, most rigorous study to date using the SPRINT® PNS System for chronic axial low back pain (LBP), patients that failed to find relief from...
Multi-center Study Demonstrates Significant Reductions in Postoperative Pain and Opioid Use Following Peripheral Nerve Stimulation Treatment
April 26, 2021 09:41 ET
|
SPR Therapeutics, Inc.
CLEVELAND, April 26, 2021 (GLOBE NEWSWIRE) -- Results of a multicenter trial recently published in Anesthesiology, the official peer-reviewed journal of the American Society of Anesthesiologists,...
Researchers Unveil a New Theory Explaining Long-term Pain Relief
March 15, 2021 09:30 ET
|
SPR Therapeutics, Inc.
CLEVELAND, March 15, 2021 (GLOBE NEWSWIRE) -- A novel theory recently published in the Journal of Pain Research proposes mechanisms by which a 60-day treatment using percutaneous peripheral nerve...
SPRINT® PNS System Demonstrates the Important Role of the Multifidus in Treating Recurrent Low Back Pain Following RFA
March 02, 2021 10:45 ET
|
SPR Therapeutics, Inc.
CLEVELAND, March 02, 2021 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc., a leader in neurostimulation technology for pain management, announced publication of clinical data evaluating the impact of...